Report Overview

The global bronchiolitis obliterans syndrome market is expected to witness a CAGR of 4.6% during the forecast period.

Market Fundamental 

Bronchiolitis Obliterans Syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the principal factor limiting long-term transplant survival. Treatment and prevention of BOS is quite challenging. Currently, there is no approved or standard treatment for BOS and successful treatment is defined as stabilization or reduction in the rate of FEV1 decline. Treatment of bronchiolitis obliterans syndrome after lung transplant involves augmenting immunosuppression since it is thought to be a form of chronic rejection. Hence, increasing or adding immunosuppressive agents like tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone has been used to treat bronchiolitis obliterans syndrome after transplant. Furthermore, shortness of breath, a dry cough, and respiratory disease are all potential symptoms of bronchiolitis obliterans. A chest CT scan, pulmonary infection test, chest x-ray, and pulmonary function test can all be used to identify bronchiolytis obliterans. Respiratory conditions (asthma, CFTR, COPD), arthritis, chemotherapy or radiation therapy, and scleroderma are risk factors for broncholytis obliterans. Despite the lack of an effective treatment on the market for bronchiolitis obliterans, corticosteroids can help clear mucus from the lungs, lessen inflammation, and widen the airways.

Market Dynamics 

One of the key factors fuelling the growth of the obliterative bronchiolitis syndrome market is the rise in the number of patients suffering from the condition worldwide. The increase in the prevalence of numerous osteoarticular illnesses, including rheumatoid arthritis and asthma, as well as chronic lung disorders including COPD and asthma, contributes to the market's rapid expansion. The market is also influenced by ongoing research to improve diagnostic methods and therapeutic options, as well as rising public awareness of lung disorders. Additionally, market is positively impacted by population growth, improved healthcare infrastructure, a surge in healthcare spending, and increased pollution levels. 

Market Ecosystem 

The globalbronchiolitis obliterans syndrome has been analysed from three perspectives by treatment type, distribution channel and region. 

Bronchiolitis Obliterans Syndrome Market by Treatment Type 

[23812739]

Based on treatment type, the global bronchiolitis obliterans syndrome market has been segmented into corticosteroids, inhaled cyclosporine and others. The corticosteroids segment dominated the segment during forecast period. Systemic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT) despite their poor efficacy and disabling side effects. The use of corticosteroids with prednisone at 1-1.5 mg/kg/day over 4-6 weeks or pulsed corticosteroid dosing with methylprednisolone (10 mg/kg/day + 3 days every month up to 6 cycles) has been reported. 

Bronchiolitis Obliterans Syndrome Market by Distribution Channel 

Based on distribution channel, the global bronchiolitis obliterans syndrome market has been segmented into hospital, retail and online pharmacies. The hospital pharmacies dominated the segment during forecast period due to rising prevalence to respiratory disorder.

Bronchiolitis Obliterans Syndrome Market by Region 

Based on region, the global bronchiolitis obliterans syndrome market has been segmented into North America, Europe, Asia Pacific, and Rest of the world. The North American market was estimated to have highest revenue. The growth of the market in the region is characterized by rising disease prevalence and need for treatment, together with rising disease diagnosis and adoption of cutting-edge therapies. The area holds a significant share of the global market due to these reasons, as well as the patient population's increased healthcare expenditures toward novel treatment alternatives and the presence of major businesses with their pipeline candidates and planned launches.  Additionally, due to the high prevalence of bronchiolitis obliterans, advancements in diagnostic technology, and supportive federal government initiatives within the region. Due to the expansion of the healthcare infrastructure and the region's economic growth, Asia-Pacific is anticipated to have considerable growth over the forecast period. Due to the poor economic and medical conditions in the majority of African nations, the rest of the world (RoW) is ranked fourth in the international market for bronchiolitis obliterans syndrome market.

Competitive Landscape 

Some of the prominent market player in the global bronchiolitis obliterans syndrome includes

• GSK plc.
• Sandoz Inc. 
• Genentech
• Teva Pharmaceuticals USA Inc
• Bayer Pharmaceuticals Corp
• Roxane Laboratories Inc.
• Incyte Corporation
• Impax Laboratories Inc
• Lannett Co Inc
• Zambon Pharma
• Altavant Sciences
• Koutif Therapeutics
• Breath Therapeutics

Strategic Development 

• In April 2020, Zambon reported that Liposomal Cyclosporine A for Inhalation (LCsAi), which is being developed for the treatment of Bronchiolitis Obliterans Syndrome, has received Fast Track designation from the US Food and Drug Administration (FDA).
• In May 2022, in order to begin clinical research with ALTA-2530 in post-lung transplant patients with Bronchiolitis Obliterans Syndrome, Altavant is anticipated to submit an IND in 2023. The company looked into the efficacy of ALTA-2530 for the treatment of acute and chronic chemical lung injuries brought on by the inhalation of sulphur mustard in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) at the US Department of Health and Human Services (HHS).

Frequently Asked Questions About This Report